SUMMARYManagement reported that second quarter results align with previous expectations, emphasizing a strategic transition toward high-value integrated drug delivery systems. In summary, our second quarter results were in line with our expectations, reflecting the continued strength of our strategy. As expected, the tax rate in the second quarter of 2026 was higher compared with the same period last year. In terms of investments, in terms of revenue, revenue around the Alina are already captured in 2026 in our guidance. Lisa Miles: Thank you very much, everyone, for joining us for Stevanato Group's Second Quarter 2026 Earnings Call.